Loading...

GLAND Gland Pharma Ltd Earnings Reports Announcement

Glnd

GLND

Gland Pharma Ltd

(GLAND)

2026 Announcement

One-on-One & Group Meetings

Regulatory Compliance

Earnings Call Transcript

Analyst Meetings

Audited Financial Results

Earnings Call Recording

Stock Options Grant

Audited results

Q4 FY26 results

Dividend declaration

Dividend and results

Independent Director Reappo...

Appointment of Independent ...

Postal Ballot Notice

Regulatory Compliance Certi...

Regulatory Notice

Trading Window Closure

Analyst / Institutional Inv...

Analyst / Investor Meetings

Analyst / Institutional Mee...

Analyst/Investor Meetings

USFDA tentative approval

CEO resignation

Stock options grant

Analyst / Institutional Inv...

Analyst / Institutional Mee...

Analyst / Institutional Mee...

Management Change

Analyst / Institutional Mee...

Earnings Call Transcript

Analyst / Institutional Mee...

Retirement of COO

Newspaper advertisement

Earnings Call Audio

Internal Auditors Reappoint...

Internal auditor appointment

Compliance Certificate

Earnings Conference Call

USFDA Regulatory Approval

Insider Trading Regulations

One-on-One Meeting

One-on-One Meeting

Analyst / Investor Meeting

Analyst Meetings

Q2FY26 Earnings Call

Q2 FY26 Results

Earnings Call Details

Investor Presentation

Financial Results Out

Financial Results Q2 FY26

Investor Meetings

Earnings Call Announcement

Board Meeting Notice

Compliance Certificate

Investor Meeting

Investor Meetings

Secretarial Auditors Appointed

Director Reappointment

FDA Approval Received

Investor Meetings

Investor Meetings

Investor Meeting Scheduled

Investor Meetings

FDA Approval Received

Q1FY26 Earnings Call

Q1 FY26 Results

Earnings Call Outcome

AGM Notice Published

Annual General Meeting

Earnings Call Announcement

GMP Compliance Certified

Compliance Certificate

Stock Options Granted

FDA Inspection Report

Investor Meet Scheduled

Investor Meet Scheduled

Investor Meetings

Investor Meetings

ANSM Inspection Update

Investor Meeting

Investor Meeting

Annual Compliance Report

Earnings Call Summary

Stock Options Grant

Financial Results Publication

Earnings Call Update

Management Change

Q4 FY25 Results

Investor Meet Intimation

ESOP Meeting Notification

Earnings Conference Call

RTA Contact Update

Compliance Certificate

Investor Meetings

ESOP Scheme 2025

Investor Meeting

Analyst Meeting

Management Change

Postal Ballot Notice

Employee Stock Options

FDA Inspection Conclusion

Q3 FY25 Earnings Call

Postal Ballot Notice

Investor Meetings

Q3 FY25 Results

Earnings Call Update

Email Registration Notice

FDA Inspection Update

Earnings Call Scheduled

USFDA Inspection Update

CEO Appointment

Compliance Certificate

ANSM Inspection Results

Investor Meet Scheduled

FDA Approval Granted

Management Change

Investor Meetings

FDA Approval Received

Investor Meeting Scheduled

Q2 FY25 Earnings

Postal Ballot Notice

Investor Meetings

Analyst Meeting

Financial Results

Earnings Call Update

Director Appointment

Investor Presentation

Shareholder Notice

Earnings Call Announcement

Management Change

Regulatory Compliance

Investor Meeting

Investor Meeting Scheduled

Management Change

Investor Meeting

Investor Meeting

Investor Meeting Schedule

Director Departure

Investor Meeting

Investor Meeting Scheduled

Management Change

Q1 FY25 Earnings

Notice of AGM and Dividend ...

Analyst Meeting Intimation

Financial Results Publication

Earnings Call Recording

Investor Presentation

Financial Results Announcement

FDA Inspection Conclusion

46th AGM Announcement

US FDA Approval

Earnings Conference Call

Certificate Confirmation

Equity Shares Allotment

Appointment Announcement

Change in Directorate

Meeting Intimation

Meeting Intimation

Change in Management

Earnings Call Transcript

Submission of Annual Secret...

Meeting Intimation

US FDA Inspection

Advertisement Publication

Earnings Call Recording

Investor Presentation

Financial Results Press Rel...

Earnings Call Rescheduled

Earnings Conference Call

Gland Pharma FDA Approval

FDA Approval for Plerixafor

Management Change

FDA Approval Received

Certificate Submission

Compliance Certificate Subm...

Gland Pharma Certificate

Increase in Volumes

Approval for Eribulin Mesyl...

Analyst Meeting

Equity Allotment

Management Change

Analyst Meeting

Analyst/Investor Meetings

Analyst Meeting Schedule

Scheduled Meeting

Analyst Meeting Schedule

Appointment of President

Earnings Call Transcript

Meeting Intimation

Financial Results

Earnings Call Recording

Financial Results Q3FY24

Q3FY24 Financial Results

Equity Allotment

Investor Conferences

Conference Call

Confirmation Certificate

Meeting Schedule

Analyst/Investor Meeting

FDA Inspection Closure

Investor Meeting

Reappointment of Independen...

Analyst/Investor Meet

US FDA Approval

Meeting Schedule

Earnings call Transcript - ...

Receipt of EIR from US FDA

Analyst Meeting

Publication of Financial Re...

Earnings Call Recording

Financial Results

Investor Presentation

Newspaper Publication

Board Meeting and Earnings ...

Reappointment of Independen...

Equity Shares Allotted on E...

US FDA Inspection

Investor Meeting

Investor Meeting

Investor Conference

Management Appointment

Analyst/Investor Meetings

Investor Meeting

Investor Conferences

Meeting Schedule

Schedule Announcement

Management Change

Investor Conference

Appointment of Statutory Au...

Inspection Observations

Newspaper Advertisement

Conclusion of Inspection

Analyst Meeting

Analyst / Investor Meet

Financial Statements

Investor Meetings

Financial Statements

Earnings Guidance

Notice of Annual General Me...

Financial Statements

Financial Statements

Earnings Guidance, Financia...

Conclusion of Inspection

Post-Market Surveillance

Financial Statements

Conclusion of Inspection

Analyst/Investor Meeting

Analyst/Investor Meet - Int...

Meeting Schedule

Meeting Schedule

Analyst/Investor Meet

Earnings Transcript

Analyst / Investor Meet

Analyst/Institutional Inves...

Analyst/Investor Meet

Publication of financial re...

Related Party Transactions

Financial Statements Approval

Financial Statements

Financial Statements

Compliance Report submission

External Links:

Data:

Gland Pharma reports Q4FY26 audited results with unmodified audit opinion and recommends a final dividend of ₹20 per share; record date Aug 11, 2026 and AGM on Aug 25, 2026.

AI Assistant

Gland Pharma Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.